Regeneron (REGN) and Sanofi (SNY) announced that the FDA has accepted for review the resubmission of the supplemental Biologics License ...

Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activityMore than 300,000 people in the U.S.

Unite.AI is committed to rigorous editorial standards. We may receive compensation when you click on links to products we review. Please view our affiliate disclosure. Creating a strong brand identity ...

Dupixent (dupilumab) is a brand-name subcutaneous injection that’s prescribed for certain inflammatory conditions. Dupixent has interactions with some other drugs. Examples include certain ...

Eli Lilly (NYSE:LLY) said a Phase 3b study of its drug Ebglyss showed it was able to improve skin and itch in patients with moderate-to-severe atopic dermatitis who had previously been treated ...

Meanwhile, the company's Pharma segment generated €8.3B in sales with ~10% YoY growth as Dupixent sales rose ~22% YoY to €3.4B, prompting the company to reaffirm its €13B full-year sales ...

Sanofi reaffirms that Dupixent will deliver around 13 billion euros in 2024 sales. The company reported third-quarter sales of 13.44 billion euros or $14.79 billion, beating the consensus of $13. ...

Quarterly revenues from its best-selling anti-inflammatory shot Dupixent gained a currency-adjusted 23.8% to 3.48 billion euros, slightly ahead of expectations. Yet more growth momentum is on the ...

Sales increased 12.3% year over year and 15.7% on constant currency, led by solid growth from Dupixent, Pharma launches, vaccines, and Opella. The French drugmaker reported adjusted EPS of 2.86 ...

(Bloomberg) -- Sanofi profit rose on demand for seasonal vaccines and further growth in its blockbuster skin and asthma therapy Dupixent. Earnings per share excluding some items reached €2.86 ($ ...

Sanofi's existing product line boasts several top-tier drugs, including immunology drug Dupixent, an IL-4/IL-13 inhibitor. Dupixent looks well positioned to reach peak sales of over EUR 18 billion ...

TARRYTOWN, N.Y. and PARIS, Oct. 24, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi will present positive data from the Phase 3 LIBERTY-CUPID Study C evaluating the ...